<DOC>
	<DOCNO>NCT00072722</DOCNO>
	<brief_summary>Phase II randomize open-label , two-arm study safety efficacy CC-4047 subject metastatic hormone refractory prostate cancer ( HRPC )</brief_summary>
	<brief_title>Safety Efficacy CC-4047 Subjects With Metastatic Hormone Refractory Prostate Cancer ( HRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Adult male subject , age 18 old time signing informed consent form Able adhere study visit schedule protocol requirement Histologically confirm adenocarcinoma prostate radiographic evidence metastasis PSA progression follow hormonal therapy metastatic disease . Subjects must evidence progression disease demonstrate 2 consecutive rise PSA ( absolute change least 1ng/ml ) separate least 28 day . Antiandrogen therapy must stop least 4 week ( flutamide ) 6 week ( bicalutamide nilutamide ) prior enter study evidence rise PSA ( baseline ) measure x 2 least 2 week apart Testicular androgen suppression must maintain either LHRH therapy bilateral orchiectomy . Must use barrier contraception ( latex condom ) engage reproductive activity woman childbearing potential throughout course study treatment 4 week follow discontinuation study treatment . May one prior regimen chemotherapy prostate cancer . The chemotherapy must stop least 4 week prior study entry . Diseasefree malignancy great 5 year exception curatively treat basal cell , squamous cell carcinoma skin Ta transitional cell carcinoma bladder . ECOG performance status 0 1 . Serum creatinine great equal 2.0 mg % Adequate hematologic function : Granulocytes great equal 1800 mm3 platelet great equal 100,000 mm3 . Adequate hepatocellular function : AST &lt; 2 x normal bilirubin &lt; 1.5mg/dl No active unresolved infection Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Any condition , include presence laboratory abnormality , place subject unacceptable risk participate study confound ability interpret data study . Use experimental drug therapy within 28 day baseline . Any prior use CC4047 Thalidomide Tumors contain small cell sarcomatoid element Symptomatic bone metastasis . Concurrent use anticancer agent . Known brain disease symptomatic , currently treat corticosteroid , previously irradiate . NonPSA produce tumor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic Hormone Refractory Prostate Cancer</keyword>
	<keyword>CC4047</keyword>
	<keyword>CC-4047</keyword>
	<keyword>Prostate Carcinoma</keyword>
	<keyword>Celgene</keyword>
</DOC>